Newer GLMs, especially sodium glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1RAs), have been increasingly prescribed to non-transplant patients with chronic kidney disease (CKD), with or without T2D [5]. This evidence concerns the gene GLP1R and chronic kidney disease.